Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies

Inclusion Criteria: * Relapsed or refractory B-cell non-Hodgkins Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) * Participants must have received at least one prior line of therapy with an anti-CD20 antibody (i.e. rituximab, ofatumumab, etc.) or an anti-CD20 antibody containing regimen * Measurable or evaluable Disease * Eastern Cooperative Oncology Group performance status 0, 1 or 2 * Participants ineligible for high dose or combination chemotherapy + stem cell transplant * No active or chronic infection of Hepatitis B or C and no history of HIV based on negative serology * All study participants must be registered into the mandatory RevAssist® program, and be willing and able to comply with the requirements of RevAssist® Exclusion Criteria: * Prior chemotherapy, investigational therapy or radiotherapy within 3 weeks of study entry * Prior autologous or allogeneic stem cell transplantation within 6 months of study entry * History of severe hypersensitivity or anaphylaxis to prior murine or mouse/human chimeric antibodies, or to any component of ublituximab, or with prior lenalidomide or thalidomide * Uncontrolled inter-current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness that would limit compliance with study requirements * History of deep vein thrombosis (DVT) or pulmonary embolus (PE) in the six months prior to Day 1 of Cycle 1 * Pregnant women